Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kite Strikes CAR-T Access & Discount Deal For Tecartus In England

UK Patients Will Be Among The First In The World To Be Offered Access To Tecartus

Executive Summary

Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.

You may also be interested in...



Scottish Funding Wins for Kite’s CAR-T Tecartus & Five Other Products

A total of six medicines were recommended for use on the National Health Service in Scotland in August.

Can The UK Remain A First Launch Market?

More political support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.

Gilead’s Trodelvy To Test UK Innovative Drug Pathway

The cancer drug is also to undergo an accelerated assessment by the European Medicines Agency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel